PETRA affords high scalability and flexibility, as no pre-engineering or elaborate assay optimisation is required. We demonstrate PETRA across four loci in Jurkat cells and two loci in primary T cells, scoring over 14,000 engineered sequences in total.
Highlights of our Results are as follows: 3/9
